Coya Therapeutics is building upon its collaboration with the Houston Methodist Research Institute, in Texas, to advance research into exosomes, or tiny packets released from regulatory T-cells (Tregs), a type of immune cells that keep inflammation in check. These exosomes contain molecules that, similar to Tregs, can cross the…
News
Researchers at University College London (UCL) have developed a test that accurately identified Parkinson’s disease up to seven years before its symptoms manifested by measuring levels of eight biomarkers in the blood, a study reports. “We set out to use state-of-the-art technology to find new and better biomarkers for…
A magnetic resonance imaging (MRI)-guided approach known as the ClearPoint Navigation System is being used in a Phase 1/2a clinical trial to enable the precise surgical delivery of ANPD001, an investigational stem cell therapy for Parkinson’s disease, its developer, Aspen Neuroscience, announced. The open-label ASPIRO trial…
Remote health monitoring company Empatica is partnering with the consortium Mobilise-D to advance the use of digital endpoints in clinical care and research across disorders that include Parkinson’s disease. The collaboration will integrate Mobilise-D’s validated digital mobility outcomes (DMOs) with Empatica’s Health Monitoring Platform. With this,…
Researchers at the University of Birmingham have shown that reducing dopamine signaling in the brain can impair people’s ability to recognize emotions or understand others’ mental states (mentalizing), symptoms that may be experienced by those with Parkinson’s disease. The study, “Disruption of dopamine D2/D3 system function impairs the…
Merck, in collaboration with the Michael J. Fox Foundation for Parkinson’s Research (MJFF), is providing a service to the scientific community to detect low levels of phospho-serine [pS65]-Ub, a biomarker associated with nerve cell dysfunction in people with Parkinson’s disease. The SMCxPRO platform is an ultrasensitive…
Patient enrollment is now complete in a Phase 2 trial that’s assessing the safety and efficacy of oral risvodetinib, being developed by Inhibikase Therapeutics to slow or stop the progression of Parkinson’s disease. The 201 trial (NCT05424276) has enrolled 120 participants across 32 sites in the U.S.,…
Changes in how regions of the brain interact with each other, which occur during the surgical procedure for deep brain stimulation (DBS), can temporarily ease motor symptoms of Parkinson’s disease, even before the electrical stimulation is turned on, a study finds. The microlesion effect, as this temporary improvement…
Scientists at the University of Dundee in Scotland said they have uncovered the mechanisms behind the activation of the PINK1 protein, an enzyme that protects the brain against nerve cell degeneration and the development of Parkinson’s disease. They discovered how PINK1, which detects damage in mitochondria — the cell’s…
Remote assessments using smartphones and smartwatches could be used to detect and monitor changes in the early stages of Parkinson’s disease, according to findings from the WATCH-PD study. Over the course of one-year of follow-up, an Apple Watch paired with an iPhone was able to…
Recent Posts
- Merz honors resiliency of Parkinson’s community with new US campaign
- Lessons revealed in the quiet moments of Parkinson’s caregiving
- Gut immune cells may help Parkinson’s spread from the belly to the brain
- New delivery system guides curcumin to Parkinson’s-affected brain cells
- New $2M MJFF grant backs Parkinson’s walking study at Boston University